期刊文献+

华法林稳定剂量预测模型对新疆肺栓塞患者预测准确性的验证与评价 被引量:3

Validation and evaluation of the predictive accuracy of warfarin stable dose prediction algorithm for patients with pulmonary embolism in Xinjiang
原文传递
导出
摘要 目的验证与评价12个华法林稳定剂量预测模型对肺栓塞患者的预测准确性。方法收集已达到华法林稳定剂量的131例肺栓塞患者完整临床资料,采集每位患者外周血2 mL,用聚合酶链反应-基因芯片杂交技术检测其细胞色素P450酶2C9(CYP2C9)和维生素K环氧化物还原酶复合体亚单位1(VKORC1)基因型,并对患者基因型分布特征和实际稳定剂量与不同基因型之间的差异进行分析。挑选出符合标准的12个华法林稳定剂量预测模型,用绝对误差均值和预测百分比评价并比较各模型预测准确性。结果 131例患者的VKORC1 AA型、GA型及GG型华法林实际稳定剂量分别为(2.76±0.78),(3.57±0.78)和(4.67±0.74)mg·d^(-1),组间比较差异有统计学意义(P<0.001)。除去CYP2C9中只有1例患者的基因型,在129例患者的实际稳定剂量中,CYP2C9*1/*1型患者高于*1/*3型患者,差异有统计学意义(P<0.05)。在12个华法林稳定剂量预测模型中,MAE最低的3个模型是都丽萍、SCONCE和吴超君,理想百分比最高的3个模型是都丽萍、吴超君和OHNO。敏感性分析显示,在8个模型的理想预测百分比大于40%中,稳定剂量预测模型对高、中、低3个剂量患者预测准确性依次下降。结论对高、中2个剂量的肺栓塞患者,都丽萍模型有很好的预测准确性;而吴超君模型相较于其他模型,对低剂量患者有较好的预测准确性。 Objective To validate and evaluate the predictive accuracy of 12 warfarin stable dose prediction algorithms for pulmonary embolism patients in the First Affiliated Hospital of Xinjiang Medical University. Methods The complete clinical data of 131 patients with stable warfarin dose were collected. Two mL of peripheral blood was collected from each patient, and the cytochrome P450 2 C9( CYP2 C9),vitamin K epoxide reductase complex 1(VKORC1)genotypes were detected by polymerase chain reation-microarray hybridization technology. Genotypes distribution characteristics and actual stable dose with differences between different genotypes were analyzed.Twelve stable dose prediction algorithms of warfarin were selected through previous publications. Mean absolute error(MAE) and prediction percentage were used to evaluate and compare the prediction accuracy of each algorithm. Results Among the 131 patients,the actual stable dose of warfarin of VKORC1 AA,GA and GG were( 2. 76 ± 0. 78),( 3. 57 ± 0. 78)and( 4. 67 ± 0. 74) mg · d^(-1),with statistically significant difference between groups( P < 0. 001). Remove the genotype of only one patient in CYP2C9,among the 129 patients,the actual stable dose of warfarin in CYP2C9* 1/* 1 genotype was higher than that in * 1/* 3 genotype,with significant differences( P < 0. 05). Among the 12 warfarin stable dose prediction algorithms,the MAE of DU Li-ping,SCONCE and WU Chao-jun in algorithms were lowest,and the ideal percentage of DU Li-ping,WU Chao-jun and OHNO in algorithms were highest. The ideal prediction percentage of 8 algorithms was greater than 40%,and the sensitivity analysis showed that the accuracy of stable dose prediction model for high,medium and low dose patients declined in turn. Conclusion DU Li-ping model has a good prediction accuracy for patients with pulmonary embolism in Xinjiang with high and medium doses,and WU Chao-jun model has better predictive accuracy than other models for patients with low doses.
作者 安晓婕 蒲文 袁圆 郦昱琨 袁双丽 吾斯曼江·艾麦提 赵军 AN Xiao-jie;PU Wen;YUAN Yuan;LI Yu-kun;YUAN Shuang-li;WU SIMANJIANG·Aimaiti;ZHAO Jun(Department of Pharmacy,The First Affiliated Hospital of Xinjiang Medical University,Ummqi 830054,Xinjiang Uygur Autonomous Region,China;Pharmacy College,Xinjiang Medical University,Urumqi 830011,Xinjiang Uygur Autonomous Region,China)
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2021年第9期1039-1043,共5页 The Chinese Journal of Clinical Pharmacology
基金 科技部国家重点研发计划课题基金资助项目(2017YFC0910001)。
关键词 华法林 肺栓塞 稳定剂量预测模型 细胞色素P450酶2C9 维生素K环氧化物还原酶复合体亚单位1 warfarin pulmonary embolism stable dose prediction algorithm cytochrome P4502C9 vitamin K epoxide reductase complex 1
  • 相关文献

参考文献5

二级参考文献67

  • 1Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent ad- verse effect resulting in regulatory action[J]. Arch Intern Med, 2007, 167(13): 1414-1419.
  • 2Klein TE, Altman RB, Eriksson N,et al. Estima- tion of the warfarin dose with clinical and pharma- cogenetic data[J]. N EnglJ Med, 2009, 360(8): 753-764.
  • 3Gage BF, Eby C, Johnson JA,et al. Use of phar- maeogenetic and clinical faetors to predict the ther- apeutic dose of warfarin[J]. Clin Pharmacol Ther, 2008, 84(3): 326-331.
  • 4Wen MS, Lee M, Chen JJ,et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes [J]. Clin Pharmacol T- her, 2008, 84(1): 83-89. pharmacogenetic algorithms.
  • 5Huang SW, Chen HS, Wang XQ, et al. Validation of VKORC1 and CYP2C9 genotypes on interindi- vidual warfarin maintenance dose: a prospective study in Chinese patients[J]. Pharmacogenet Ge- nomics, 2009, 19(3): 226-234.
  • 6Wadelius M, Chen LY, Lindh JD,et al. The largest prospective warfarin treated cohort supports genet- ic forecasting[J]. Blood, 2009, 113(4): 784- 792.
  • 7Marin-Leblanc M, Perreault S, Bahroun I, et al. Validation of warfarin in clinical praetice[J]. Pharmacogenomics, 2012, 13(1): 21-29.
  • 8Liu Y, Yang J, Xu Q,et al. Comparative perform ance of warfarin pharmacogenetic algoritlams in Chinese patients[J]. Thromb Res, 2012.
  • 9Cho H J, On YK, Bang OY, et al. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation[J]. Clin Ther, 2011, 33(10): 1371-1380.
  • 10Zhimin W, Yubao Z, Lei S, et al. Prevalence of chronic rheumatic heart disease in Chinese adults [J]. Int J Cardiol, 2006, 107(3): 356 -359.

共引文献56

同被引文献28

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部